•Lucid shares plunged as much as 49% following reports that the company is working with restructuring adviser AlixPartners to evaluate strategic options.
•Strategic options under consideration reportedly include a take-private transaction or a Chapter 11 bankruptcy filing.
•Advisers are reportedly urging the board to focus on the Gravity SUV and conduct another round of restructuring in the US and Europe.
•Innovent Biologics signed an exclusive license agreement with Spero Therapeutics to develop and commercialize the SP001 antibody worldwide, excluding Greater China.
•Innovent will receive an upfront payment and is eligible for development, regulatory, and commercial milestones totaling approximately $1.1 billion.
•Spero plans to initiate a Phase 2 study for IgG4-RD patients in the second quarter of 2027.
•Crude oil prices declined after President Trump backed away from a proposal to impose a 20% reimbursement fee on cargo ships exiting the Strait of Hormuz.
•The administration is shifting focus toward securing investment commitments in the United States instead of the proposed fee.
•The price is currently testing significant technical support levels at $77.84 following the pullback from recent resistance.
